Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
RNA silencing
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "RNA silencing" in MCE Product Catalog:
Target:
Domaines de recherche:
SPEN-IN-1 (compound X1) is an inhibitor of SPEN which is a protein factor with a Kd value of 47 nM. SPEN-IN-1 has high selectivity for RepA, a 431-nucleotide domain in Xist (a non-coding RNA prototype) that comprises 8.5 units of a GC-rich motif responsible for gene silencing .
LNP Lipid-8 (11-A-M) is an ionizable single-tail multi-head lipid that can be used as a lipid nanoparticle (LNP) to deliver siRNA to T cells without targeting ligands. LNP Lipid-8 is more selective for T cells than other cell types such as hepatocytes. LNP Lipid-8 selectively delivers siRNA/sgRNA to T cells (especially CD8+ T cells) through endogenous lipid transport pathways, and can enter cells and release RNA through endocytosis to achieve gene silencing. LNP Lipid-8 loaded with GFP siRNA (siGFP) significantly led to GFP gene silencing in mouse models. LNP Lipid-8 showed good efficacy and safety in both cells and animals, without obvious liver targeting and toxicity. LNP Lipid-8 can be used for RNA delivery research in the fields of tumor immunotherapy and T cell-mediated autoimmune diseases .
Cat. No.: HY-177640
CAS No.: 2808361-18-2
Synonyms: LY3819469
Domaines de recherche:
Lepodisiran (LY3819469) is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran can be used in studies related to atherosclerotic cardiovascular disease .
Cat. No.: HY-164583
CAS No.: 2923115-67-5
Target:
Domaines de recherche:
DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite is an RNA phosphoramidite monomer. DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite allows site-specific introduction of a 2'-O-C22 lipophilic modification at adenosine positions to construct double-stranded RNA (dsRNA) molecules with extrahepatic delivery capability. DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite supports target gene silencing in skeletal muscle, cardiac muscle and adipose tissue by enhancing the lipophilicity and tissue uptake efficiency of dsRNA. DMTr-2'-O-C22-rA-3'-CE-Phosphoramidite can be used for the construction and mechanism research of nucleic acid silencing molecules .
Cat. No.: HY-153484A
CAS No.: 849758-52-7
Target:
Domaines de recherche:
Bevasiranib sodium is a siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib sodium distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib sodium can be used in research related to macular degeneration .
Cat. No.: HY-78574
CAS No.: 13089-48-0
Target:
Domaines de recherche:
N-Benzoylcytidine is a modified cytidine analogue that can be phosphorylated by uracil-cytidine kinase (UCK1 and UCK2). N-Benzoylcytidine can be used to synthesize 2-OH protective groups for solid-phase RNA synthesis, as well as synthetic oligonucleotides for UV induction and targeted gene silencing in zebrafish embryos .
Cat. No.: HY-164582
CAS No.: 2923115-93-7
Target:
Domaines de recherche:
DMTr-2'-O-C22-rC (Ac)-3'-CE-Phosphoramidite is an RNA phosphoramidite monomer. DMTr-2'-O-C22-rC (Ac)-3'-CE-Phosphoramidite enables site-specific introduction of 2'-O-C22 lipophilic modification at cytidine positions during oligonucleotide synthesis, which is used to construct double-stranded RNA (dsRNA) molecules with extrahepatic delivery capability. DMTr-2'-O-C22-rC (Ac)-3'-CE-Phosphoramidite supports target gene silencing in skeletal muscle, cardiac muscle and adipose tissue by enhancing the lipophilicity and tissue uptake efficiency of dsRNA. Construction and mechanism study of DMTr-2'-O-C22-rC (Ac)-3'-CE-Phosphoramidite nucleic acid silencing molecules .
Cat. No.: HY-164581
CAS No.: 2923115-75-5
Target:
Domaines de recherche:
DMTr-2'-O-C22-rG (ibu)-3'-CE-Phosphoramidite is an RNA phosphoramidite monomer for oligonucleotide synthesis. DMTr-2'-O-C22-rG (ibu)-3'-CE-Phosphoramidite enables site-specific introduction of 2'-O-C22 lipophilic modification at guanosine positions to construct double-stranded RNA (dsRNA) molecules with extrahepatic delivery capability. DMTr-2'-O-C22-rG (ibu)-3'-CE-Phosphoramidite supports target gene silencing in skeletal muscle, cardiac muscle and adipose tissue by enhancing the lipid solubility and tissue uptake efficiency of dsRNA. DMTr-2'-O-C22-rG (ibu)-3'-CE-Phosphoramidite can be used for the construction and mechanism research of nucleic acid silencing molecules .
Cat. No.: HY-177640A
CAS No.: 2766131-24-0
Synonyms: LY3819469 sodium
Domaines de recherche:
Lepodisiran (LY3819469) sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
Cat. No.: HY-114901
CAS No.: 186141-75-3
Target:
Domaines de recherche:
A-134974 is a selective adenosine kinase (ADK) inhibitor, with an IC50 of 0.06 nM and 45 nM in rat brain cytoplasmic ADK enzyme assays and intact IMR-32 cells, respectively . A-134974 inhibits adenosine phosphorylation and elevates intracellular and extracellular adenosine levels, alleviates neuropathic tactile allodynia and inflammatory thermal hyperalgesia via endogenous adenosine signaling in the spinal cord, and shows favorable dose separation between its analgesic effects and motor function impairment . A-134974 can be used in research on neuropathic pain, inflammatory pain, RNA silencing and thermoregulation .
Cat. No.: HY-153484
CAS No.: 959961-96-7
Target:
Domaines de recherche:
Bevasiranib is a siRNA that targets and silences VEGF-A. Bevasiranib activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib can be used in research related to macular degeneration .
Cat. No.: HY-145649A
CAS No.: 2380166-34-5
Synonyms: AD-85481 sodium; ALN-AGT sodium
Domaines de recherche:
Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension .
Cat. No.: HY-153484D
Target:
Domaines de recherche:
FAM labled Bevasiranib sodiumis a FAM labled Bevasiranib sodium. Bevasiranib sodium is an siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA and can be used in research related to macular degeneration.
Cat. No.: HY-153484E
Target:
Domaines de recherche:
Cy3-labeled Bevasiranib sodium is Bevasiranib sodium conjugated with the Cy3 fluorophore. Bevasiranib sodium is an siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex (RISC) to degrade VEGF-A mRNA and can be used in research related to macular degeneration.
Cat. No.: HY-177640C
Domaines de recherche:
FAM labled Lepodisiran (LY3819469) sodiumis a FAM labled Lepodisiran sodium. Lepodisiran sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
Cat. No.: HY-177640D
Domaines de recherche:
Cy3 labled Lepodisiran (LY3819469) sodium is a Cy3 labled Lepodisiran sodium. Lepodisiran sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
